- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.00 Å
- Oligo State
- homo-10-mer
- Ligands
- 10 x ACY: ACETIC ACID(Non-functional Binders)
- 4 x DTU: (2R,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL(Non-covalent)
DTU.2: 6 residues within 4Å:- Chain A: D.14, A.15, C.46, V.144, L.147, A.148
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:D.14, A:D.14
DTU.8: 5 residues within 4Å:- Chain B: C.46, V.144, L.147, A.148, L.151
No protein-ligand interaction detected (PLIP)DTU.31: 6 residues within 4Å:- Chain F: D.14, A.15, C.46, V.144, L.147, A.148
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:D.14
DTU.37: 5 residues within 4Å:- Chain G: C.46, V.144, L.147, A.148, L.151
No protein-ligand interaction detected (PLIP)- 2 x T1P: 3-{2,6,8-TRIOXO-9-[(2R,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
T1P.3: 18 residues within 4Å:- Chain A: W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain B: A.113, N.114, R.128, K.138, A.142
21 PLIP interactions:4 interactions with chain B, 17 interactions with chain A- Hydrogen bonds: B:N.114, B:K.138, A:A.59, A:I.60, A:E.61, A:V.81, A:I.83, A:G.85, A:Q.86, A:T.87, A:T.87
- Water bridges: B:R.128, A:W.27, A:V.81, A:Q.86, A:F.90
- Salt bridges: B:R.128
- pi-Stacking: A:W.27, A:W.27, A:W.27, A:W.27
T1P.32: 18 residues within 4Å:- Chain F: W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain G: A.113, N.114, R.128, K.138, A.142
21 PLIP interactions:17 interactions with chain F, 4 interactions with chain G- Hydrogen bonds: F:A.59, F:I.60, F:E.61, F:V.81, F:I.83, F:G.85, F:Q.86, F:T.87, G:N.114, G:K.138
- Water bridges: F:W.27, F:V.81, F:Q.86, F:T.87, F:F.90, G:R.128
- pi-Stacking: F:W.27, F:W.27, F:W.27, F:W.27
- Salt bridges: G:R.128
- 26 x K: POTASSIUM ION(Non-covalent)
K.4: 3 residues within 4Å:- Chain A: A.70, H.73, T.110
Ligand excluded by PLIPK.5: 5 residues within 4Å:- Chain A: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.6: 7 residues within 4Å:- Chain A: L.156, R.157
- Chain F: E.155, L.156, R.157, H.159
- Ligands: K.35
Ligand excluded by PLIPK.10: 3 residues within 4Å:- Chain B: A.70, H.73, T.110
Ligand excluded by PLIPK.11: 5 residues within 4Å:- Chain B: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.12: 7 residues within 4Å:- Chain B: E.155, L.156, R.157, H.159
- Chain J: L.156, R.157, H.159
Ligand excluded by PLIPK.16: 3 residues within 4Å:- Chain C: A.70, H.73, T.110
Ligand excluded by PLIPK.17: 5 residues within 4Å:- Chain C: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.18: 8 residues within 4Å:- Chain C: E.155, L.156, R.157, H.159
- Chain I: E.155, L.156, R.157, H.159
Ligand excluded by PLIPK.22: 3 residues within 4Å:- Chain D: A.70, H.73, T.110
Ligand excluded by PLIPK.23: 5 residues within 4Å:- Chain D: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.27: 3 residues within 4Å:- Chain E: A.70, H.73, T.110
Ligand excluded by PLIPK.28: 5 residues within 4Å:- Chain E: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.33: 3 residues within 4Å:- Chain F: A.70, H.73, T.110
Ligand excluded by PLIPK.34: 5 residues within 4Å:- Chain F: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.35: 7 residues within 4Å:- Chain A: E.155, L.156, R.157, H.159
- Chain F: L.156, R.157
- Ligands: K.6
Ligand excluded by PLIPK.39: 3 residues within 4Å:- Chain G: A.70, H.73, T.110
Ligand excluded by PLIPK.40: 5 residues within 4Å:- Chain G: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.41: 7 residues within 4Å:- Chain E: L.156, R.157, H.159
- Chain G: E.155, L.156, R.157, H.159
Ligand excluded by PLIPK.45: 3 residues within 4Å:- Chain H: A.70, H.73, T.110
Ligand excluded by PLIPK.46: 5 residues within 4Å:- Chain H: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.47: 8 residues within 4Å:- Chain D: E.155, L.156, R.157, H.159
- Chain H: E.155, L.156, R.157, H.159
Ligand excluded by PLIPK.51: 3 residues within 4Å:- Chain I: A.70, H.73, T.110
Ligand excluded by PLIPK.52: 5 residues within 4Å:- Chain I: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIPK.56: 3 residues within 4Å:- Chain J: A.70, H.73, T.110
Ligand excluded by PLIPK.57: 5 residues within 4Å:- Chain J: A.34, G.38, A.129, G.130, D.137
Ligand excluded by PLIP- 2 x T2P: 3-{2,6,8-TRIOXO-9-[(2S,3R,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
T2P.9: 18 residues within 4Å:- Chain B: W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain C: A.113, N.114, R.128, K.138, A.145
19 PLIP interactions:14 interactions with chain B, 5 interactions with chain C- Hydrogen bonds: B:S.25, B:A.59, B:I.60, B:E.61, B:V.81, B:I.83, B:Q.86, B:T.87, C:N.114, C:K.138
- Water bridges: B:V.81, B:G.85, B:F.90, C:N.114, C:K.138
- pi-Stacking: B:W.27, B:W.27, B:W.27
- Salt bridges: C:R.128
T2P.38: 18 residues within 4Å:- Chain G: W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain H: A.113, N.114, R.128, K.138, A.145
20 PLIP interactions:15 interactions with chain G, 5 interactions with chain H- Hydrogen bonds: G:S.25, G:A.59, G:I.60, G:E.61, G:V.81, G:I.83, G:Q.86, G:T.87, G:H.89, H:N.114, H:K.138
- Water bridges: G:V.81, G:G.85, G:F.90, H:N.114, H:K.138
- pi-Stacking: G:W.27, G:W.27, G:W.27
- Salt bridges: H:R.128
- 6 x DTV: (2S,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL(Non-covalent)
DTV.14: 4 residues within 4Å:- Chain C: A.15, C.46, A.148, L.151
No protein-ligand interaction detected (PLIP)DTV.20: 7 residues within 4Å:- Chain D: D.14, A.15, C.46, V.144, L.147, A.148, L.151
No protein-ligand interaction detected (PLIP)DTV.25: 5 residues within 4Å:- Chain E: A.15, C.46, V.144, L.151
- Ligands: D1D.29
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:V.144
DTV.43: 4 residues within 4Å:- Chain H: A.15, C.46, A.148, L.151
No protein-ligand interaction detected (PLIP)DTV.49: 7 residues within 4Å:- Chain I: D.14, A.15, C.46, V.144, L.147, A.148, L.151
No protein-ligand interaction detected (PLIP)DTV.54: 5 residues within 4Å:- Chain J: A.15, C.46, V.144, L.151
- Ligands: D1D.58
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:V.144
- 2 x T5P: 3-{2,6,8-TRIOXO-9-[(2S,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
T5P.15: 18 residues within 4Å:- Chain C: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain D: A.113, N.114, R.128, K.138
21 PLIP interactions:5 interactions with chain D, 16 interactions with chain C- Hydrogen bonds: D:N.114, D:K.138, C:S.25, C:A.59, C:I.60, C:E.61, C:V.81, C:I.83, C:Q.86, C:T.87
- Water bridges: D:I.112, D:R.128, C:W.27, C:W.27, C:E.61, C:G.85, C:Q.86
- Salt bridges: D:R.128
- pi-Stacking: C:W.27, C:W.27, C:W.27
T5P.44: 18 residues within 4Å:- Chain H: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain I: A.113, N.114, R.128, K.138
21 PLIP interactions:16 interactions with chain H, 5 interactions with chain I- Hydrogen bonds: H:S.25, H:A.59, H:I.60, H:E.61, H:V.81, H:I.83, H:Q.86, H:T.87, I:N.114, I:K.138
- Water bridges: H:W.27, H:W.27, H:E.61, H:G.85, H:Q.86, I:I.112, I:R.128
- pi-Stacking: H:W.27, H:W.27, H:W.27
- Salt bridges: I:R.128
- 4 x T4P: 3-{2,6,8-TRIOXO-9-[(2R,3R,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
T4P.21: 18 residues within 4Å:- Chain D: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain E: A.113, N.114, R.128, K.138
18 PLIP interactions:3 interactions with chain E, 15 interactions with chain D- Hydrogen bonds: E:N.114, E:K.138, D:S.25, D:G.58, D:A.59, D:I.60, D:V.81, D:I.83, D:Q.86, D:T.87
- Salt bridges: E:R.128
- Water bridges: D:W.27, D:V.81, D:G.85, D:G.85
- pi-Stacking: D:W.27, D:W.27, D:W.27
T4P.26: 20 residues within 4Å:- Chain A: A.113, N.114, R.128, K.138, A.142, A.145
- Chain E: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
22 PLIP interactions:17 interactions with chain E, 5 interactions with chain A- Hydrogen bonds: E:S.25, E:G.58, E:A.59, E:I.60, E:V.81, E:I.83, E:Q.86, E:T.87, E:H.89, A:N.114, A:K.138
- Water bridges: E:V.81, E:G.85, E:T.87, E:T.87, E:F.90, A:R.128, A:R.128
- pi-Stacking: E:W.27, E:W.27, E:W.27
- Salt bridges: A:R.128
T4P.50: 18 residues within 4Å:- Chain I: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
- Chain J: A.113, N.114, R.128, K.138
18 PLIP interactions:15 interactions with chain I, 3 interactions with chain J- Hydrogen bonds: I:S.25, I:G.58, I:A.59, I:I.60, I:V.81, I:I.83, I:Q.86, I:T.87, J:N.114, J:K.138
- Water bridges: I:W.27, I:V.81, I:G.85, I:G.85
- pi-Stacking: I:W.27, I:W.27, I:W.27
- Salt bridges: J:R.128
T4P.55: 20 residues within 4Å:- Chain F: A.113, N.114, R.128, K.138, A.142, A.145
- Chain J: S.25, W.27, H.28, G.58, A.59, I.60, E.61, V.81, V.82, I.83, G.85, Q.86, T.87, H.89
20 PLIP interactions:15 interactions with chain J, 5 interactions with chain F- Hydrogen bonds: J:S.25, J:G.58, J:A.59, J:I.60, J:V.81, J:I.83, J:Q.86, J:T.87, J:H.89, F:N.114, F:K.138
- Water bridges: J:V.81, J:G.85, J:F.90, F:R.128, F:R.128
- pi-Stacking: J:W.27, J:W.27, J:W.27
- Salt bridges: F:R.128
- 2 x D1D: (4S,5S)-1,2-DITHIANE-4,5-DIOL(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Morgunova, E. et al., Crystal Structure of Lumazine Synthase from Mycobacterium Tuberculosis as a Target for Rational Drug Design: Binding Mode of a New Class of Purinetrione Inhibitors(,). Biochemistry (2005)
- Release Date
- 2005-03-02
- Peptides
- 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE: ABCDEFGHIJ
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
AG
BH
CI
DJ
E
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.00 Å
- Oligo State
- homo-10-mer
- Ligands
- 10 x ACY: ACETIC ACID(Non-functional Binders)
- 4 x DTU: (2R,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL(Non-covalent)
- 2 x T1P: 3-{2,6,8-TRIOXO-9-[(2R,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
- 26 x K: POTASSIUM ION(Non-covalent)
- 2 x T2P: 3-{2,6,8-TRIOXO-9-[(2S,3R,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
- 6 x DTV: (2S,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL(Non-covalent)
- 2 x T5P: 3-{2,6,8-TRIOXO-9-[(2S,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
- 4 x T4P: 3-{2,6,8-TRIOXO-9-[(2R,3R,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-1,2,3,6,8,9-HEXAHYDRO-7H-PURIN-7-YL}PROPYL DIHYDROGEN PHOSPHATE(Non-covalent)
- 2 x D1D: (4S,5S)-1,2-DITHIANE-4,5-DIOL(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Morgunova, E. et al., Crystal Structure of Lumazine Synthase from Mycobacterium Tuberculosis as a Target for Rational Drug Design: Binding Mode of a New Class of Purinetrione Inhibitors(,). Biochemistry (2005)
- Release Date
- 2005-03-02
- Peptides
- 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE: ABCDEFGHIJ
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
AG
BH
CI
DJ
E